Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| HUMANIGEN, INCKBIO · Entity 108862 | Director | September 13, 2016 | September 15, 2016 |
| Pelthos Therapeutics Inc.PTHS · Entity 6798 | Director | October 02, 2026 | October 06, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
HUMANIGEN, INC
Report date September 13, 2016 · Filed September 15, 2016
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.38 · Expires 2026-09-12 | Direct | 100,000 |
Reported balance
After 2016-09-13 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2016-09-13 · Grant · Acquired 100,000 · Balance 100,000 F1: The option vests and becomes exercisable in 12 equal quarterly installments beginning on December 13, 2016. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests and becomes exercisable in 12 equal quarterly installments beginning on December 13, 2016.
Pelthos Therapeutics Inc.
Report date October 02, 2026 · Filed October 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 80,484 |
Reported balance
After 2026-10-02 transaction · row 1
1 source rowRow 1 · 2026-10-02 · Sale · Disposed 558 · Balance 80,484 F1: This transaction reflects the sale of shares, made pursuant to a Rule 10b5-1 plan adopted December 16, 2025, for the purpose of satisfying estimated tax obligations in connection with the vesting of restricted stock units granted by the Issuer. |
| Common StockSEC Table I · non-derivative | IndirectBy Balmoral Financial Group LLC | 82,072 |
Reported balance
Holding disclosure · report date 2026-10-02 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 82,072 F2: Ezra Friedberg is the manager of Balmoral Financial Group LLC ("Balmoral") and the manager of Key Recovery Group LLC ("Key"). By virtue of this relationship, Mr. Friedberg may be deemed to beneficially own the shares of Common Stock held of record by each of Balmoral and Key. Mr. Friedberg disclaims any such beneficial ownership except to the extent of his pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Key Recovery Group LLC | 40,000 |
Reported balance
Holding disclosure · report date 2026-10-02 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 40,000 F2: Ezra Friedberg is the manager of Balmoral Financial Group LLC ("Balmoral") and the manager of Key Recovery Group LLC ("Key"). By virtue of this relationship, Mr. Friedberg may be deemed to beneficially own the shares of Common Stock held of record by each of Balmoral and Key. Mr. Friedberg disclaims any such beneficial ownership except to the extent of his pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction reflects the sale of shares, made pursuant to a Rule 10b5-1 plan adopted December 16, 2025, for the purpose of satisfying estimated tax obligations in connection with the vesting of restricted stock units granted by the Issuer.
F2: Ezra Friedberg is the manager of Balmoral Financial Group LLC ("Balmoral") and the manager of Key Recovery Group LLC ("Key"). By virtue of this relationship, Mr. Friedberg may be deemed to beneficially own the shares of Common Stock held of record by each of Balmoral and Key. Mr. Friedberg disclaims any such beneficial ownership except to the extent of his pecuniary interest therein.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 02, 2026 Filed Oct 6, 2026 21:53 UTC | Pelthos Therapeutics Inc. PTHS · Entity 6798 | SaleCommon Stock | 558 | $20.72 | $11,560.03 |
DisclosureSEC source: 0001919246-26-000130 · wk-form4_1791323632.xml · nonDerivative · entry 1 Friedberg Ezra M · CIK 0001679440 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 80,484 F1 · kind: This transaction reflects the sale of shares, made pursuant to a Rule 10b5-1 plan adopted December 16, 2025, for the purpose of satisfying estimated tax obligations in connection with the vesting of restricted stock units granted by the Issuer. Read SEC document |
| July 02, 2026 Filed Jul 7, 2026 21:03 UTC | Pelthos Therapeutics Inc. PTHS · Entity 6798 | SaleCommon Stock | 24 | $27.33 | $655.81 |
DisclosureSEC source: 0001919246-26-000102 · wk-form4_1783458235.xml · nonDerivative · entry 2 Friedberg Ezra M · CIK 0001679440 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 81,042 F1 · kind: This transaction reflects the sale of shares, made pursuant to a Rule 10b5-1 plan adopted December 16, 2025, for the purpose of satisfying estimated tax obligations in connection with the vesting of restricted stock units granted by the Issuer. F3 · price: This transaction was executed in multiple trades at prices ranging from $27.20 to $27.63. The price reported in column 4 above reflects the weighted average price of the shares of Common Stock sold. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 02, 2026 Filed Jul 7, 2026 21:03 UTC | Pelthos Therapeutics Inc. PTHS · Entity 6798 | SaleCommon Stock | 534 | $26.03 | $13,900.18 |
DisclosureSEC source: 0001919246-26-000102 · wk-form4_1783458235.xml · nonDerivative · entry 1 Friedberg Ezra M · CIK 0001679440 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 81,066 F1 · kind: This transaction reflects the sale of shares, made pursuant to a Rule 10b5-1 plan adopted December 16, 2025, for the purpose of satisfying estimated tax obligations in connection with the vesting of restricted stock units granted by the Issuer. F2 · price: This transaction was executed in multiple trades at prices ranging from $25.58 to $26.24. The price reported in column 4 above reflects the weighted average price of the shares of Common Stock sold. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 15, 2026 Filed Jun 17, 2026 21:25 UTC | Pelthos Therapeutics Inc. PTHS · Entity 6798 | SaleCommon Stock | 59 | $27.94 | $1,648.48 |
DisclosureSEC source: 0001919246-26-000093 · wk-form4_1781731506.xml · nonDerivative · entry 2 Friedberg Ezra M · CIK 0001679440 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 81,600 F1 · kind: This transaction reflects the sale of shares, made pursuant to a Rule 10b5-1 plan adopted December 16, 2025, for the purpose of satisfying estimated tax obligations in connection with the vesting of restricted stock units granted by the Issuer. F3 · price: This transaction was executed in multiple trades at prices ranging from $27.92 to $28.00. The price reported in column 4 above reflects the weighted average price of the shares of Common Stock sold. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 15, 2026 Filed Jun 17, 2026 21:25 UTC | Pelthos Therapeutics Inc. PTHS · Entity 6798 | SaleCommon Stock | 224 | $27.12 | $6,075.89 |
DisclosureSEC source: 0001919246-26-000093 · wk-form4_1781731506.xml · nonDerivative · entry 1 Friedberg Ezra M · CIK 0001679440 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 81,659 F1 · kind: This transaction reflects the sale of shares, made pursuant to a Rule 10b5-1 plan adopted December 16, 2025, for the purpose of satisfying estimated tax obligations in connection with the vesting of restricted stock units granted by the Issuer. F2 · price: This transaction was executed in multiple trades at prices ranging from $26.71 to $27.44. The price reported in column 4 above reflects the weighted average price of the shares of Common Stock sold. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 14, 2026 Filed May 18, 2026 22:11 UTC | Pelthos Therapeutics Inc. PTHS · Entity 6798 | Tax withholdingCommon Stock | 144 | $27.01 | $3,889.01 |
DisclosureSEC source: 0001919246-26-000073 · wk-form4_1779142269.xml · nonDerivative · entry 1 Friedberg Ezra M · CIK 0001679440 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 81,883 F1 · kind: This transaction reflects the sale of shares, made pursuant to a Rule 10b5-1 plan adopted December 16, 2025, for the purpose of satisfying estimated tax obligations in connection with the vesting of restricted stock units granted by the Issuer. F2 · price: This transaction was executed in multiple trades at prices ranging from $27.00 to $27.0101. The price reported in column 4 above reflects the weighted average price of the shares of Common Stock sold. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 02, 2026 Filed Apr 6, 2026 21:03 UTC | Pelthos Therapeutics Inc. PTHS · Entity 6798 | SaleCommon Stock | 265 | $21.36 | $5,660.72 |
DisclosureSEC source: 0001919246-26-000054 · wk-form4_1775509382.xml · nonDerivative · entry 2 Friedberg Ezra M · CIK 0001679440 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 82,027 F1 · kind: This transaction reflects the sale of shares, made pursuant to a Rule 10b5-1 plan adopted December 16, 2025, for the purpose of satisfying estimated tax obligations in connection with the vesting of restricted stock units granted by the Issuer. F3 · price: This transaction was executed in multiple trades at prices ranging from $21.31 to $22.03. The price reported in column 4 above reflects the weighted average price of the shares of Common Stock sold. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 02, 2026 Filed Apr 6, 2026 21:03 UTC | Pelthos Therapeutics Inc. PTHS · Entity 6798 | SaleCommon Stock | 293 | $20.51 | $6,010.05 |
DisclosureSEC source: 0001919246-26-000054 · wk-form4_1775509382.xml · nonDerivative · entry 1 Friedberg Ezra M · CIK 0001679440 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 82,292 F1 · kind: This transaction reflects the sale of shares, made pursuant to a Rule 10b5-1 plan adopted December 16, 2025, for the purpose of satisfying estimated tax obligations in connection with the vesting of restricted stock units granted by the Issuer. F2 · price: This transaction was executed in multiple trades at prices ranging from $20.30 to $20.78. The price reported in column 4 above reflects the weighted average price of the shares of Common Stock sold. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 25, 2025 Filed Nov 26, 2025 17:37 UTC | Pelthos Therapeutics Inc. PTHS · Entity 6798 | SaleCommon Stock | 2,000 | $28.01 | $56,010.00 |
DisclosureSEC source: 0001753926-25-001831 · ownership.xml · nonDerivative · entry 4 Friedberg Ezra M · CIK 0001679440 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Balmoral Financial Group LLC Disclosed balance after: 30,000 F1 · ownership.nature: Ezra Friedberg is the manager of Balmoral Financial Group LLC ("Balmoral") and the manager of Key Recovery Group LLC ("Key"). By virtue of this relationship, Mr. Friedberg may be deemed to beneficially own the shares of Common Stock held of record by each of Balmoral and Key. Mr. Friedberg disclaims any such beneficial ownership except to the extent of his pecuniary interest therein. Read SEC document |
| November 25, 2025 Filed Nov 26, 2025 17:37 UTC | Pelthos Therapeutics Inc. PTHS · Entity 6798 | SaleCommon Stock | 1 | $28.50 | $28.50 |
DisclosureSEC source: 0001753926-25-001831 · ownership.xml · nonDerivative · entry 3 Friedberg Ezra M · CIK 0001679440 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Balmoral Financial Group LLC Disclosed balance after: 32,000 F1 · ownership.nature: Ezra Friedberg is the manager of Balmoral Financial Group LLC ("Balmoral") and the manager of Key Recovery Group LLC ("Key"). By virtue of this relationship, Mr. Friedberg may be deemed to beneficially own the shares of Common Stock held of record by each of Balmoral and Key. Mr. Friedberg disclaims any such beneficial ownership except to the extent of his pecuniary interest therein. Read SEC document |
| November 25, 2025 Filed Nov 26, 2025 17:37 UTC | Pelthos Therapeutics Inc. PTHS · Entity 6798 | SaleCommon Stock | 2,000 | $28.14 | $56,270.00 |
DisclosureSEC source: 0001753926-25-001831 · ownership.xml · nonDerivative · entry 2 Friedberg Ezra M · CIK 0001679440 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Balmoral Financial Group LLC Disclosed balance after: 32,001 F1 · ownership.nature: Ezra Friedberg is the manager of Balmoral Financial Group LLC ("Balmoral") and the manager of Key Recovery Group LLC ("Key"). By virtue of this relationship, Mr. Friedberg may be deemed to beneficially own the shares of Common Stock held of record by each of Balmoral and Key. Mr. Friedberg disclaims any such beneficial ownership except to the extent of his pecuniary interest therein. Read SEC document |
| November 25, 2025 Filed Nov 26, 2025 17:37 UTC | Pelthos Therapeutics Inc. PTHS · Entity 6798 | SaleCommon Stock | 5,999 | $28.00 | $167,972.00 |
DisclosureSEC source: 0001753926-25-001831 · ownership.xml · nonDerivative · entry 1 Friedberg Ezra M · CIK 0001679440 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Balmoral Financial Group LLC Disclosed balance after: 34,001 F1 · ownership.nature: Ezra Friedberg is the manager of Balmoral Financial Group LLC ("Balmoral") and the manager of Key Recovery Group LLC ("Key"). By virtue of this relationship, Mr. Friedberg may be deemed to beneficially own the shares of Common Stock held of record by each of Balmoral and Key. Mr. Friedberg disclaims any such beneficial ownership except to the extent of his pecuniary interest therein. Read SEC document |
| July 02, 2025 Filed Jul 8, 2025 01:42 UTC | Pelthos Therapeutics Inc. PTHS · Entity 6798 | GrantStock Option · Derivative | 58,230 | Not disclosed Strike: $13.50 | Not disclosed |
DisclosureSEC source: 0001753926-25-001104 · ownership.xml · derivative · entry 2 Friedberg Ezra M · CIK 0001679440 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,230 Underlying: Common Stock · 58,230 shares Expires 2035-07-02 F2 · price: On July 2, 2025, the Reporting Person was granted stock options to purchase 58,230 shares of common stock at an exercise price of $13.50 per share, which shall vest on a quarterly basis over a period of three (3) years. F2 · derivative.exercise_date: On July 2, 2025, the Reporting Person was granted stock options to purchase 58,230 shares of common stock at an exercise price of $13.50 per share, which shall vest on a quarterly basis over a period of three (3) years. Read SEC document |
| July 02, 2025 Filed Jul 8, 2025 01:42 UTC | Pelthos Therapeutics Inc. PTHS · Entity 6798 | GrantRestricted Stock Units · Derivative | 19,108 | Not disclosed Strike: $13.50 | Not disclosed |
DisclosureSEC source: 0001753926-25-001104 · ownership.xml · derivative · entry 1 Friedberg Ezra M · CIK 0001679440 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,012 Underlying: Common Stock · 19,108 shares Expires 2035-07-02 F1 · price: On July 2, 2025, the Reporting Person was granted stock restricted stock units to purchase 19,108 shares of common stock at an exercise price of $13.50 per share, which shall vest on a quarterly basis over a period of three (3) years. F1 · derivative.exercise_date: On July 2, 2025, the Reporting Person was granted stock restricted stock units to purchase 19,108 shares of common stock at an exercise price of $13.50 per share, which shall vest on a quarterly basis over a period of three (3) years. F3 · balance_after: The numbers reported herein have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025. Read SEC document |
| July 02, 2025 Filed Apr 1, 2026 21:45 UTC Amendment | Pelthos Therapeutics Inc. PTHS · Entity 6798 | GrantCommon Stock | 19,108 | $0.00 | $0.00 |
DisclosureSEC source: 0001919246-26-000047 · wk-form4a_1775079936.xml · nonDerivative · entry 3 Friedberg Ezra M · CIK 0001679440 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 82,585 F1 · security: From June 18, 2024 to July 7, 2025, the reporting person filed multiple Form 4s relating to shares of common stock, par value $0.0001 per share ("Common Stock") of Pelthos Therapeutics Inc. (the "Issuer"), issuable upon settlement of restricted stock units of the Issuer ("RSUs") granted to the reporting person pursuant to the Issuer's 2023 Equity Incentive Plan, as amended from time to time (the "2023 Plan"), each of which represents the right to receive one (1) share of Common Stock, subject to the vesting terms of such RSUs, and may be settled solely in shares of Common Stock. The original grant of RSUs was reported in Table II of the Form 4s filed by the reporting person (the "Original Form 4s"). This Form 4 amendment (this "Amendment") is being filed to amend the Original Form 4s in order to report the grant of such RSUs in Table I. F2 · shares: The RSUs were received as compensation for the reporting person's service as a member of the Issuer's board of directors pursuant to the 2023 Plan. The RSUs vest in equal installments on a quarterly basis after the date of such grant for a period of three years, so long as the reporting person remains in the service of the Issuer on each such anniversary. F2 · price: The RSUs were received as compensation for the reporting person's service as a member of the Issuer's board of directors pursuant to the 2023 Plan. The RSUs vest in equal installments on a quarterly basis after the date of such grant for a period of three years, so long as the reporting person remains in the service of the Issuer on each such anniversary. Read SEC document |
| July 01, 2025 Filed Jul 4, 2025 01:05 UTC | Pelthos Therapeutics Inc. PTHS · Entity 6798 | ConversionSeries A Convertible Preferred Stock · Derivative | 40,000 | $0.00 Strike: $10.00 | $0.00 |
DisclosureSEC source: 0001753926-25-001079 · ownership.xml · derivative · entry 7 Friedberg Ezra M · CIK 0001679440 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Key Recovery Group LLC Disclosed balance after: 0 Underlying: Common Stock · 40,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The numbers reported herein have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025. F3 · derivative.exercise_date: The Series A convertible preferred stock is convertible at any time, at the holder's election, and has no expiration date. The Series A convertible preferred stock is subject to a contractual limitation such that the holder may not convert Series A convertible preferred stock to the extent that after giving effect to such conversion, the holder (together with its attribution parties as defined in the certificate of designations) would beneficially own in excess of 4.99% of the shares of common stock outstanding immediately after giving effect to such conversion. F3 · derivative.expiration_date: The Series A convertible preferred stock is convertible at any time, at the holder's election, and has no expiration date. The Series A convertible preferred stock is subject to a contractual limitation such that the holder may not convert Series A convertible preferred stock to the extent that after giving effect to such conversion, the holder (together with its attribution parties as defined in the certificate of designations) would beneficially own in excess of 4.99% of the shares of common stock outstanding immediately after giving effect to such conversion. F1 · derivative.underlying_shares: The numbers reported herein have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025. F3 · balance_after: The Series A convertible preferred stock is convertible at any time, at the holder's election, and has no expiration date. The Series A convertible preferred stock is subject to a contractual limitation such that the holder may not convert Series A convertible preferred stock to the extent that after giving effect to such conversion, the holder (together with its attribution parties as defined in the certificate of designations) would beneficially own in excess of 4.99% of the shares of common stock outstanding immediately after giving effect to such conversion. F2 · ownership.nature: Ezra Friedberg is the manager of Balmoral Financial Group LLC ("Balmoral") and the manager of Key Recovery Group LLC ("Key"). By virtue of this relationship, Mr. Friedberg may be deemed to beneficially own the shares of Common Stock held of record by each of Balmoral and Key. Mr. Friedberg disclaims any such beneficial ownership except to the extent of his pecuniary interest therein. Read SEC document |
| July 01, 2025 Filed Jul 4, 2025 01:05 UTC | Pelthos Therapeutics Inc. PTHS · Entity 6798 | ConversionSeries A Convertible Preferred Stock · Derivative | 40,000 | $0.00 Strike: $10.00 | $0.00 |
DisclosureSEC source: 0001753926-25-001079 · ownership.xml · derivative · entry 6 Friedberg Ezra M · CIK 0001679440 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Balmoral Financial Group LLC Disclosed balance after: 0 Underlying: Common Stock · 40,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The numbers reported herein have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025. F3 · derivative.exercise_date: The Series A convertible preferred stock is convertible at any time, at the holder's election, and has no expiration date. The Series A convertible preferred stock is subject to a contractual limitation such that the holder may not convert Series A convertible preferred stock to the extent that after giving effect to such conversion, the holder (together with its attribution parties as defined in the certificate of designations) would beneficially own in excess of 4.99% of the shares of common stock outstanding immediately after giving effect to such conversion. F3 · derivative.expiration_date: The Series A convertible preferred stock is convertible at any time, at the holder's election, and has no expiration date. The Series A convertible preferred stock is subject to a contractual limitation such that the holder may not convert Series A convertible preferred stock to the extent that after giving effect to such conversion, the holder (together with its attribution parties as defined in the certificate of designations) would beneficially own in excess of 4.99% of the shares of common stock outstanding immediately after giving effect to such conversion. F1 · derivative.underlying_shares: The numbers reported herein have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025. F3 · balance_after: The Series A convertible preferred stock is convertible at any time, at the holder's election, and has no expiration date. The Series A convertible preferred stock is subject to a contractual limitation such that the holder may not convert Series A convertible preferred stock to the extent that after giving effect to such conversion, the holder (together with its attribution parties as defined in the certificate of designations) would beneficially own in excess of 4.99% of the shares of common stock outstanding immediately after giving effect to such conversion. F2 · ownership.nature: Ezra Friedberg is the manager of Balmoral Financial Group LLC ("Balmoral") and the manager of Key Recovery Group LLC ("Key"). By virtue of this relationship, Mr. Friedberg may be deemed to beneficially own the shares of Common Stock held of record by each of Balmoral and Key. Mr. Friedberg disclaims any such beneficial ownership except to the extent of his pecuniary interest therein. Read SEC document |
| July 01, 2025 Filed Jul 4, 2025 01:05 UTC | Pelthos Therapeutics Inc. PTHS · Entity 6798 | PurchaseSeries A Convertible Preferred Stock · Derivative | 40,000 | $0.00 Strike: $10.00 | $0.00 |
DisclosureSEC source: 0001753926-25-001079 · ownership.xml · derivative · entry 5 Friedberg Ezra M · CIK 0001679440 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Key Recovery Group LLC Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires not disclosed F1 · derivative.exercise_price: The numbers reported herein have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025. F3 · derivative.exercise_date: The Series A convertible preferred stock is convertible at any time, at the holder's election, and has no expiration date. The Series A convertible preferred stock is subject to a contractual limitation such that the holder may not convert Series A convertible preferred stock to the extent that after giving effect to such conversion, the holder (together with its attribution parties as defined in the certificate of designations) would beneficially own in excess of 4.99% of the shares of common stock outstanding immediately after giving effect to such conversion. F3 · derivative.expiration_date: The Series A convertible preferred stock is convertible at any time, at the holder's election, and has no expiration date. The Series A convertible preferred stock is subject to a contractual limitation such that the holder may not convert Series A convertible preferred stock to the extent that after giving effect to such conversion, the holder (together with its attribution parties as defined in the certificate of designations) would beneficially own in excess of 4.99% of the shares of common stock outstanding immediately after giving effect to such conversion. F1 · derivative.underlying_shares: The numbers reported herein have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025. F3 · balance_after: The Series A convertible preferred stock is convertible at any time, at the holder's election, and has no expiration date. The Series A convertible preferred stock is subject to a contractual limitation such that the holder may not convert Series A convertible preferred stock to the extent that after giving effect to such conversion, the holder (together with its attribution parties as defined in the certificate of designations) would beneficially own in excess of 4.99% of the shares of common stock outstanding immediately after giving effect to such conversion. F2 · ownership.nature: Ezra Friedberg is the manager of Balmoral Financial Group LLC ("Balmoral") and the manager of Key Recovery Group LLC ("Key"). By virtue of this relationship, Mr. Friedberg may be deemed to beneficially own the shares of Common Stock held of record by each of Balmoral and Key. Mr. Friedberg disclaims any such beneficial ownership except to the extent of his pecuniary interest therein. Read SEC document |
| July 01, 2025 Filed Jul 4, 2025 01:05 UTC | Pelthos Therapeutics Inc. PTHS · Entity 6798 | PurchaseSeries A Convertible Preferred Stock · Derivative | 40,000 | $0.00 Strike: $10.00 | $0.00 |
DisclosureSEC source: 0001753926-25-001079 · ownership.xml · derivative · entry 4 Friedberg Ezra M · CIK 0001679440 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Balmoral Financial Group LLC Disclosed balance after: 40,000 Underlying: Common Stock · 92,072 shares Expires not disclosed F1 · derivative.exercise_price: The numbers reported herein have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025. F3 · derivative.exercise_date: The Series A convertible preferred stock is convertible at any time, at the holder's election, and has no expiration date. The Series A convertible preferred stock is subject to a contractual limitation such that the holder may not convert Series A convertible preferred stock to the extent that after giving effect to such conversion, the holder (together with its attribution parties as defined in the certificate of designations) would beneficially own in excess of 4.99% of the shares of common stock outstanding immediately after giving effect to such conversion. F3 · derivative.expiration_date: The Series A convertible preferred stock is convertible at any time, at the holder's election, and has no expiration date. The Series A convertible preferred stock is subject to a contractual limitation such that the holder may not convert Series A convertible preferred stock to the extent that after giving effect to such conversion, the holder (together with its attribution parties as defined in the certificate of designations) would beneficially own in excess of 4.99% of the shares of common stock outstanding immediately after giving effect to such conversion. F1 · derivative.underlying_shares: The numbers reported herein have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025. F3 · balance_after: The Series A convertible preferred stock is convertible at any time, at the holder's election, and has no expiration date. The Series A convertible preferred stock is subject to a contractual limitation such that the holder may not convert Series A convertible preferred stock to the extent that after giving effect to such conversion, the holder (together with its attribution parties as defined in the certificate of designations) would beneficially own in excess of 4.99% of the shares of common stock outstanding immediately after giving effect to such conversion. F2 · ownership.nature: Ezra Friedberg is the manager of Balmoral Financial Group LLC ("Balmoral") and the manager of Key Recovery Group LLC ("Key"). By virtue of this relationship, Mr. Friedberg may be deemed to beneficially own the shares of Common Stock held of record by each of Balmoral and Key. Mr. Friedberg disclaims any such beneficial ownership except to the extent of his pecuniary interest therein. Read SEC document |
| July 01, 2025 Filed Jul 4, 2025 01:05 UTC | Pelthos Therapeutics Inc. PTHS · Entity 6798 | ConversionCommon Stock | 40,000 | $10.00 | $400,000.00 |
DisclosureSEC source: 0001753926-25-001079 · ownership.xml · nonDerivative · entry 2 Friedberg Ezra M · CIK 0001679440 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Key Recovery Group LLC Disclosed balance after: 40,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The numbers reported herein have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025. F1 · price: The numbers reported herein have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025. F1 · balance_after: The numbers reported herein have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025. F2 · ownership.nature: Ezra Friedberg is the manager of Balmoral Financial Group LLC ("Balmoral") and the manager of Key Recovery Group LLC ("Key"). By virtue of this relationship, Mr. Friedberg may be deemed to beneficially own the shares of Common Stock held of record by each of Balmoral and Key. Mr. Friedberg disclaims any such beneficial ownership except to the extent of his pecuniary interest therein. Read SEC document |
| July 01, 2025 Filed Jul 4, 2025 01:05 UTC | Pelthos Therapeutics Inc. PTHS · Entity 6798 | ConversionCommon Stock | 40,000 | $10.00 | $400,000.00 |
DisclosureSEC source: 0001753926-25-001079 · ownership.xml · nonDerivative · entry 1 Friedberg Ezra M · CIK 0001679440 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Balmoral Financial Group LLC Disclosed balance after: 40,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The numbers reported herein have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025. F1 · price: The numbers reported herein have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025. F1 · balance_after: The numbers reported herein have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025. F2 · ownership.nature: Ezra Friedberg is the manager of Balmoral Financial Group LLC ("Balmoral") and the manager of Key Recovery Group LLC ("Key"). By virtue of this relationship, Mr. Friedberg may be deemed to beneficially own the shares of Common Stock held of record by each of Balmoral and Key. Mr. Friedberg disclaims any such beneficial ownership except to the extent of his pecuniary interest therein. Read SEC document |
| November 13, 2024 Filed Nov 15, 2024 21:19 UTC | Pelthos Therapeutics Inc. CHRO · Entity 6798 | GrantRestricted Stock Units · Derivative | 24,533 | Not disclosed Strike: $0.64 | Not disclosed |
DisclosureSEC source: 0001753926-24-001947 · ownership.xml · derivative · entry 1 Friedberg Ezra M · CIK 0001679440 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 634,752 Underlying: Common Stock · 24,533 shares Expires 2024-11-13 F1 · price: On November 13, 2024, the Reporting Person was granted restricted stock units to purchase 24,533 shares of common stock at an exercise price of $0.64 per share, which shall vest on a quarterly basis over a period of six (6) quarters. F1 · derivative.exercise_date: On November 13, 2024, the Reporting Person was granted restricted stock units to purchase 24,533 shares of common stock at an exercise price of $0.64 per share, which shall vest on a quarterly basis over a period of six (6) quarters. Read SEC document |
| November 13, 2024 Filed Apr 1, 2026 21:45 UTC Amendment | Pelthos Therapeutics Inc. PTHS · Entity 6798 | GrantCommon Stock | 2,454 | $0.00 | $0.00 |
DisclosureSEC source: 0001919246-26-000047 · wk-form4a_1775079936.xml · nonDerivative · entry 2 Friedberg Ezra M · CIK 0001679440 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,477 F1 · security: From June 18, 2024 to July 7, 2025, the reporting person filed multiple Form 4s relating to shares of common stock, par value $0.0001 per share ("Common Stock") of Pelthos Therapeutics Inc. (the "Issuer"), issuable upon settlement of restricted stock units of the Issuer ("RSUs") granted to the reporting person pursuant to the Issuer's 2023 Equity Incentive Plan, as amended from time to time (the "2023 Plan"), each of which represents the right to receive one (1) share of Common Stock, subject to the vesting terms of such RSUs, and may be settled solely in shares of Common Stock. The original grant of RSUs was reported in Table II of the Form 4s filed by the reporting person (the "Original Form 4s"). This Form 4 amendment (this "Amendment") is being filed to amend the Original Form 4s in order to report the grant of such RSUs in Table I. F2 · shares: The RSUs were received as compensation for the reporting person's service as a member of the Issuer's board of directors pursuant to the 2023 Plan. The RSUs vest in equal installments on a quarterly basis after the date of such grant for a period of three years, so long as the reporting person remains in the service of the Issuer on each such anniversary. F2 · price: The RSUs were received as compensation for the reporting person's service as a member of the Issuer's board of directors pursuant to the 2023 Plan. The RSUs vest in equal installments on a quarterly basis after the date of such grant for a period of three years, so long as the reporting person remains in the service of the Issuer on each such anniversary. F3 · balance_after: Amounts have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025. Read SEC document |
| June 14, 2024 Filed Jun 19, 2024 00:03 UTC | Pelthos Therapeutics Inc. CHRO · Entity 6798 | GrantRestricted Stock Units · Derivative | 64,498 | Not disclosed Strike: $1.30 | Not disclosed |
DisclosureSEC source: 0001753926-24-001133 · ownership.xml · derivative · entry 1 Friedberg Ezra M · CIK 0001679440 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 610,219 Underlying: Common Stock · 64,498 shares Expires 2034-06-14 F1 · price: On June 14, 2024, the Reporting Person was granted restricted stock units to purchase 64,498 shares of common stock at an exercise price of $1.30 per share, which shall vest on a quarterly basis over a period of two (2) years. F1 · derivative.exercise_date: On June 14, 2024, the Reporting Person was granted restricted stock units to purchase 64,498 shares of common stock at an exercise price of $1.30 per share, which shall vest on a quarterly basis over a period of two (2) years. Read SEC document |
| June 14, 2024 Filed Apr 1, 2026 21:45 UTC Amendment | Pelthos Therapeutics Inc. PTHS · Entity 6798 | GrantCommon Stock | 6,450 | $0.00 | $0.00 |
DisclosureSEC source: 0001919246-26-000047 · wk-form4a_1775079936.xml · nonDerivative · entry 1 Friedberg Ezra M · CIK 0001679440 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,023 F1 · security: From June 18, 2024 to July 7, 2025, the reporting person filed multiple Form 4s relating to shares of common stock, par value $0.0001 per share ("Common Stock") of Pelthos Therapeutics Inc. (the "Issuer"), issuable upon settlement of restricted stock units of the Issuer ("RSUs") granted to the reporting person pursuant to the Issuer's 2023 Equity Incentive Plan, as amended from time to time (the "2023 Plan"), each of which represents the right to receive one (1) share of Common Stock, subject to the vesting terms of such RSUs, and may be settled solely in shares of Common Stock. The original grant of RSUs was reported in Table II of the Form 4s filed by the reporting person (the "Original Form 4s"). This Form 4 amendment (this "Amendment") is being filed to amend the Original Form 4s in order to report the grant of such RSUs in Table I. F2 · shares: The RSUs were received as compensation for the reporting person's service as a member of the Issuer's board of directors pursuant to the 2023 Plan. The RSUs vest in equal installments on a quarterly basis after the date of such grant for a period of three years, so long as the reporting person remains in the service of the Issuer on each such anniversary. F2 · price: The RSUs were received as compensation for the reporting person's service as a member of the Issuer's board of directors pursuant to the 2023 Plan. The RSUs vest in equal installments on a quarterly basis after the date of such grant for a period of three years, so long as the reporting person remains in the service of the Issuer on each such anniversary. F3 · balance_after: Amounts have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025. Read SEC document |
| February 21, 2024 Filed Feb 23, 2024 22:12 UTC | Pelthos Therapeutics Inc. CHRO · Entity 6798 | ConversionSecured Convertible Promissory Note · Derivative | 33,136 | Not disclosed Strike: $4.80 | Not disclosed |
DisclosureSEC source: 0001753926-24-000372 · ownership.xml · derivative · entry 4 Friedberg Ezra M · CIK 0001679440 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Balmoral Financial Group LLC Disclosed balance after: 0 Underlying: Common Stock · 6,992 shares Expires 2024-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Represents $33,136.00 of outstanding principal and accrued and unpaid interest of this senior secured convertible promissory note, due March 1, 2024, which automatically converted into 6,992 shares of common stock of the Issuer at a conversion price of 80.0% of the offering price of the securities sold to the public in the Issuer's initial public offering, including an additional 88 shares of common stock issued as consideration for this senior secured convertible promissory note. F3 · price: Represents $33,136.00 of outstanding principal and accrued and unpaid interest of this senior secured convertible promissory note, due March 1, 2024, which automatically converted into 6,992 shares of common stock of the Issuer at a conversion price of 80.0% of the offering price of the securities sold to the public in the Issuer's initial public offering, including an additional 88 shares of common stock issued as consideration for this senior secured convertible promissory note. F1 · ownership.nature: The securities are held by Balmoral Financial Group LLC ("Balmoral"). The Reporting Person serves as a manager of Balmoral, which also manages a retirement account for the Reporting Person, and, accordingly, the Reporting Person may also be deemed to beneficially own the shares of common stock held by Balmoral (or managed by Balmoral, in respect of the retirement account). Read SEC document |
| February 21, 2024 Filed Feb 23, 2024 22:12 UTC | Pelthos Therapeutics Inc. CHRO · Entity 6798 | ConversionSecured Convertible Promissory Note · Derivative | 65,513.61 | Not disclosed Strike: $4.80 | Not disclosed |
DisclosureSEC source: 0001753926-24-000372 · ownership.xml · derivative · entry 3 Friedberg Ezra M · CIK 0001679440 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Balmoral Financial Group LLC Disclosed balance after: 0 Underlying: Common Stock · 13,649 shares Expires 2024-02-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Represents $65,513.61 of outstanding principal and accrued and unpaid interest of this senior secured convertible promissory note, due February 29, 2024, which automatically converted into 13,649 shares of common stock of the Issuer at a conversion price of 80.0% of the offering price of the securities sold to the public in the Issuer's initial public offering. F2 · price: Represents $65,513.61 of outstanding principal and accrued and unpaid interest of this senior secured convertible promissory note, due February 29, 2024, which automatically converted into 13,649 shares of common stock of the Issuer at a conversion price of 80.0% of the offering price of the securities sold to the public in the Issuer's initial public offering. F1 · ownership.nature: The securities are held by Balmoral Financial Group LLC ("Balmoral"). The Reporting Person serves as a manager of Balmoral, which also manages a retirement account for the Reporting Person, and, accordingly, the Reporting Person may also be deemed to beneficially own the shares of common stock held by Balmoral (or managed by Balmoral, in respect of the retirement account). Read SEC document |
| February 21, 2024 Filed Feb 23, 2024 22:12 UTC | Pelthos Therapeutics Inc. CHRO · Entity 6798 | Exercise / conversionCommon Stock | 6,992 | $4.80 | $33,561.60 |
DisclosureSEC source: 0001753926-24-000372 · ownership.xml · nonDerivative · entry 2 Friedberg Ezra M · CIK 0001679440 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Balmoral Financial Group LLC Disclosed balance after: 520,719 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: Represents $33,136.00 of outstanding principal and accrued and unpaid interest of this senior secured convertible promissory note, due March 1, 2024, which automatically converted into 6,992 shares of common stock of the Issuer at a conversion price of 80.0% of the offering price of the securities sold to the public in the Issuer's initial public offering, including an additional 88 shares of common stock issued as consideration for this senior secured convertible promissory note. F3 · shares: Represents $33,136.00 of outstanding principal and accrued and unpaid interest of this senior secured convertible promissory note, due March 1, 2024, which automatically converted into 6,992 shares of common stock of the Issuer at a conversion price of 80.0% of the offering price of the securities sold to the public in the Issuer's initial public offering, including an additional 88 shares of common stock issued as consideration for this senior secured convertible promissory note. F3 · price: Represents $33,136.00 of outstanding principal and accrued and unpaid interest of this senior secured convertible promissory note, due March 1, 2024, which automatically converted into 6,992 shares of common stock of the Issuer at a conversion price of 80.0% of the offering price of the securities sold to the public in the Issuer's initial public offering, including an additional 88 shares of common stock issued as consideration for this senior secured convertible promissory note. F1 · ownership.nature: The securities are held by Balmoral Financial Group LLC ("Balmoral"). The Reporting Person serves as a manager of Balmoral, which also manages a retirement account for the Reporting Person, and, accordingly, the Reporting Person may also be deemed to beneficially own the shares of common stock held by Balmoral (or managed by Balmoral, in respect of the retirement account). Read SEC document |
| February 21, 2024 Filed Feb 23, 2024 22:12 UTC | Pelthos Therapeutics Inc. CHRO · Entity 6798 | Exercise / conversionCommon Stock | 13,649 | $4.80 | $65,515.20 |
DisclosureSEC source: 0001753926-24-000372 · ownership.xml · nonDerivative · entry 1 Friedberg Ezra M · CIK 0001679440 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Balmoral Financial Group LLC Disclosed balance after: 513,727 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: Represents $65,513.61 of outstanding principal and accrued and unpaid interest of this senior secured convertible promissory note, due February 29, 2024, which automatically converted into 13,649 shares of common stock of the Issuer at a conversion price of 80.0% of the offering price of the securities sold to the public in the Issuer's initial public offering. F2 · shares: Represents $65,513.61 of outstanding principal and accrued and unpaid interest of this senior secured convertible promissory note, due February 29, 2024, which automatically converted into 13,649 shares of common stock of the Issuer at a conversion price of 80.0% of the offering price of the securities sold to the public in the Issuer's initial public offering. F2 · price: Represents $65,513.61 of outstanding principal and accrued and unpaid interest of this senior secured convertible promissory note, due February 29, 2024, which automatically converted into 13,649 shares of common stock of the Issuer at a conversion price of 80.0% of the offering price of the securities sold to the public in the Issuer's initial public offering. F1 · ownership.nature: The securities are held by Balmoral Financial Group LLC ("Balmoral"). The Reporting Person serves as a manager of Balmoral, which also manages a retirement account for the Reporting Person, and, accordingly, the Reporting Person may also be deemed to beneficially own the shares of common stock held by Balmoral (or managed by Balmoral, in respect of the retirement account). Read SEC document |
| February 21, 2024 Filed Mar 12, 2024 20:05 UTC Amendment | Pelthos Therapeutics Inc. CHRO · Entity 6798 | PurchaseCommon Stock | 16,667 | $6.00 | $100,002.00 |
DisclosureSEC source: 0001753926-24-000518 · ownership.xml · nonDerivative · entry 1 Friedberg Ezra M · CIK 0001679440 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 545,721 F1 · security: This Form 4/A is being filed to include the purchase of 16,667 shares of the Issuer's common stock (the "Common Stock") in the Issuer's initial public offering, in addition to the securities originally reported on the Form 4 filed by the reporting person on February 21, 2024. F1 · kind: This Form 4/A is being filed to include the purchase of 16,667 shares of the Issuer's common stock (the "Common Stock") in the Issuer's initial public offering, in addition to the securities originally reported on the Form 4 filed by the reporting person on February 21, 2024. F1 · shares: This Form 4/A is being filed to include the purchase of 16,667 shares of the Issuer's common stock (the "Common Stock") in the Issuer's initial public offering, in addition to the securities originally reported on the Form 4 filed by the reporting person on February 21, 2024. F1 · price: This Form 4/A is being filed to include the purchase of 16,667 shares of the Issuer's common stock (the "Common Stock") in the Issuer's initial public offering, in addition to the securities originally reported on the Form 4 filed by the reporting person on February 21, 2024. F1 · balance_after: This Form 4/A is being filed to include the purchase of 16,667 shares of the Issuer's common stock (the "Common Stock") in the Issuer's initial public offering, in addition to the securities originally reported on the Form 4 filed by the reporting person on February 21, 2024. Read SEC document |
| September 13, 2016 Filed Sep 15, 2016 17:38 UTC | HUMANIGEN, INC KBIO · Entity 108862 | GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $3.38 | $0.00 |
DisclosureSEC source: 0001123292-16-002730 · edgar.xml · derivative · entry 1 Friedberg Ezra M · CIK 0001679440 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2026-09-12 F1 · derivative.exercise_date: The option vests and becomes exercisable in 12 equal quarterly installments beginning on December 13, 2016. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.